Objective. Evaluation of the efficacy and safety of netakimab as monotherapy in patients with palmoplantar psoriasis.
Methods. An open, single-center, prospective, non-randomized study was conducted at the Dermatovenereology Department of the Medsi Clinical and Diagnostic Center, Moscow. Nineteen adult patients (n=19) with widespread psoriasis and lesions of the palms and soles were followed-up for 52 weeks: 11 women (58%) and 8 men (42%), aged 34 to 72 years. Patients in an outpatient setting received monotherapy with the interleukin-17 (IL-17) inhibitor netakimab according to the standard regimen for 52 weeks. The severity of dermatosis was determined using the ppPASI (Palmoplantar Pustulosis Area and Severity Index) before the start of treatment, then every 4 weeks. The Dermatological Quality of Life Index (DQLI) was determined using a questionnaire before the start, at the 4th, 12th, 24th and 52nd weeks of treatment. The intensity of itching/pain in the affected areas of the palms and soles was determined by patients themselves using a visual analog scale (VAS) from 0 to 10 points for the last day before the start and at the 12th, 24th and 52nd weeks of treatment. The safety of netakimab was assessed based on the development of adverse events and local reactions to the administration of the drug.
Results. Netakimab monotherapy for palmar-plantar psoriasis conducted over 52 weeks proved the high clinical efficacy of the drug: by the end of the 52nd week of therapy, the ppPASI index decreased by an average of 66.0% in the group, the DIQI by 73.6%, and the intensity of itching and/or pain according to the VAS by 46.2%. No serious adverse events or early withdrawal of participants from the study for this reason were registered.
Conclusion. Netakimab monotherapy demonstrated efficacy and safety in the treatment of palmar-plantar psoriasis.

Keywords: IL-17 inhibitor, palmar-plantar psoriasis, netakimab, genetically engineered biological therapy